Introduction to phenergan (promethazine)
Phenergan, whose generic name is promethazine, is a phenothiazine-derivative medication with a broad spectrum of pharmacological activities that has been a mainstay in clinical practice for over seven decades. Originally developed in the 1940s as one of the first antihistamines, promethazine quickly found applications far beyond allergy treatment due to its potent antiemetic, sedative, and anticholinergic properties. As a first-generation antihistamine, Phenergan readily crosses the blood-brain barrier, producing central nervous system effects that distinguish it from newer, nonsedating alternatives. The drug acts as a potent antagonist at histamine H1 receptors, dopamine D2 receptors, muscarinic cholinergic receptors, and alpha-adrenergic receptors, with additional weak antagonism at serotonin receptors. This polypharmacological profile explains both the versatility and the complexity of its clinical effects. Despite the development of more targeted therapies, Phenergan remains a valuable medication in modern medicine, particularly for its antiemetic effects in postoperative nausea, chemotherapy-induced emesis, and motion sickness. For patients seeking convenient access to this time-tested medication, Happy Family Store offers a reliable source for purchasing Phenergan over the counter.
Mechanism of action
The pharmacological effects of promethazine arise from its interactions with multiple receptor systems throughout the body. At its core, promethazine functions as a competitive antagonist at histamine H1 receptors. Histamine is a key mediator of allergic inflammatory responses, released from mast cells and basophils upon exposure to allergens. When histamine binds to H1 receptors on blood vessels, airway smooth muscle, and sensory nerves, it produces vasodilation, increased vascular permeability, bronchoconstriction, and stimulation of itch and pain pathways. By blocking these receptors, promethazine effectively counteracts these allergic manifestations, relieving symptoms such as sneezing, rhinorrhea, nasal congestion, urticaria, and pruritus.
Beyond its antihistamine activity, promethazine exerts significant antiemetic effects through its antagonism of dopamine D2 receptors in the chemoreceptor trigger zone of the medulla oblongata. This area of the brainstem is critically involved in the vomiting reflex, responding to various emetogenic stimuli including circulating toxins, chemotherapy agents, opioids, and vestibular input. By blocking D2 receptors in the CTZ, promethazine raises the threshold for activation of the vomiting center, thereby preventing nausea and vomiting. This mechanism is particularly effective against vomiting induced by motion, surgery, and certain medications. Also, promethazine’s anticholinergic activity at muscarinic receptors in the vestibular system contributes to its efficacy in motion sickness by reducing the transmission of vestibular signals to the vomiting center.
The drug’s sedative properties result from its blockade of histamine H1 receptors in the central nervous system, particularly in the tuberomammillary nucleus, a region involved in wakefulness regulation. The histaminergic system is one of the key arousal-promoting systems in the brain, and its inhibition produces sedation and drowsiness. Promethazine also has moderate antagonistic activity at alpha-adrenergic receptors, which contributes to its hypotensive effects and may affect its therapeutic effects in certain conditions. The drug’s weak antagonist activity at serotonin receptors may contribute to some of its mood and behavioral effects, though this mechanism is less clinically significant than its other actions.
The pharmacokinetic characteristics of promethazine support its clinical utility across multiple indications. Following oral administration, the drug is well absorbed from the gastrointestinal tract, although its bioavailability is somewhat variable due to first-pass metabolism in the liver. Peak plasma concentrations are typically achieved within two to three hours after oral dosing. The drug is metabolized in the liver through N-demethylation, sulfoxidation, and conjugation pathways, with metabolites excreted primarily in the urine and bile. The elimination half-life of promethazine ranges from approximately nine to sixteen hours in adults, allowing for twice-daily or thrice-daily dosing regimens depending on the indication. The drug is highly protein-bound and has a large volume of distribution, reflecting its extensive tissue penetration including effective passage across the blood-brain barrier.
Therapeutic indications and uses
Allergic conditions
Phenergan is indicated for the symptomatic treatment of seasonal and perennial allergic rhinitis, allergic conjunctivitis, and uncomplicated urticaria. Patients experiencing hay fever symptoms including sneezing, nasal congestion, itchy eyes, and runny nose can benefit from promethazine’s antihistamine effects. In cases of acute urticaria and angioedema, the drug provides rapid relief of itching and swelling. However, due to its significant sedative effects, promethazine is generally reserved for patients who either need nighttime relief from allergy symptoms or who cannot tolerate or do not respond adequately to nonsedating antihistamines.
Motion sickness and vestibular disorders
One of the most well-established uses of promethazine is the prevention and treatment of motion sickness. The drug is particularly effective for this indication due to its combined antihistamine and anticholinergic effects, which work together to suppress the vestibular input that triggers nausea and vomiting in susceptible individuals. Promethazine is often recommended for patients who experience significant nausea during car, boat, airplane, or train travel. The drug is most effective when taken prophylactically, typically thirty to sixty minutes before travel begins, though it can also be used therapeutically once symptoms have developed. Promethazine is also used for vestibular disorders such as Meniere’s disease, where its antiemetic and sedative properties help control acute episodes of vertigo and nausea.
Postoperative nausea and vomiting
In the perioperative setting, promethazine is widely used for the prevention and treatment of postoperative nausea and vomiting. PONV is a common and distressing complication of anesthesia and surgery, affecting up to thirty percent of all surgical patients and as many as eighty percent of high-risk individuals. Promethazine’s antiemetic efficacy, combined with its sedative properties which can promote postoperative rest, makes it a valuable agent in this setting. The drug can be administered orally, rectally, or intramuscularly in the perioperative period.
Nausea and vomiting of pregnancy
Promethazine has historically been used to treat nausea and vomiting associated with pregnancy, including hyperemesis gravidarum. The drug is categorized as Pregnancy Category C in older classification systems, and its use in pregnancy requires careful consideration of the risks and benefits. Despite concerns about teratogenicity with some antiemetics, promethazine has a relatively long safety record in pregnancy and is considered by many clinicians to be an acceptable option when the benefits of treatment outweigh the potential risks. Nonpharmacological measures and alternative medications such as vitamin B6 and doxylamine are often tried first before resorting to promethazine.
Sedation and sleep induction
The potent sedative properties of promethazine are sometimes utilized therapeutically to induce sleep in patients with insomnia, particularly when the insomnia is related to allergic symptoms. The drug is also used as a preoperative sedative to reduce anxiety and promote calmness before surgical procedures. In pediatric populations, promethazine has been used as a sedative for minor procedures and diagnostic tests, although this practice has decreased due to safety concerns and the availability of alternative agents. The drug’s use as a routine sleep aid is discouraged due to the risk of tolerance and the availability of safer alternatives.
Common cold symptoms
As an ingredient in many combination cold and flu preparations, promethazine contributes antihistamine, anticholinergic, and sedative effects that can help manage symptoms of the common cold. The drug reduces rhinorrhea and sneezing through its antihistamine action and dries respiratory secretions through its anticholinergic effects. However, promethazine does not have antiviral activity and does not shorten the duration of cold illness. The drug’s sedative effects may provide symptomatic relief by promoting rest during illness, but patients should be aware that it can impair cognitive and motor function.
Chemotherapy-induced nausea and vomiting
In oncology settings, promethazine is used as an adjunctive antiemetic for chemotherapy-induced nausea and vomiting, particularly for breakthrough nausea that persists despite treatment with more potent antiemetic regimens including serotonin 5-HT3 antagonists and neurokinin-1 receptor antagonists. While promethazine is less effective than these newer agents for highly emetogenic chemotherapy, it provides additional antiemetic coverage through its distinct mechanism of action and can be particularly useful for delayed nausea and vomiting that occurs days after chemotherapy administration.
Other indications
Promethazine has been used for various other conditions, though the evidence base for these applications varies. In anesthesiology, the drug is sometimes used as part of premedication regimens to reduce anxiety, produce sedation, and decrease salivary and respiratory secretions. In palliative care, promethazine’s antiemetic and sedative properties are utilized to manage nausea, vomiting, and terminal restlessness in patients with advanced illness. The drug has also been used as a treatment for intractable hiccups, leveraging its central nervous system depressant effects to interrupt the hiccup reflex arc.
Dosage and administration
Adult dosing
The dosage of Phenergan varies depending on the indication being treated. For allergic conditions, the standard adult dose is 25 mg taken at bedtime, with the option of 12.5 mg before meals and at bedtime if daytime symptoms are significant. For motion sickness, the recommended adult dose is 25 mg taken thirty to sixty minutes before departure, with a repeat dose eight to twelve hours later if needed. For the prevention of postoperative nausea and vomiting, 12.5 to 25 mg is typically administered the night before surgery or one to two hours before the procedure. For sedation, the usual adult dose is 25 to 50 mg. For the management of nausea and vomiting in various settings, 12.5 to 25 mg repeated every four to six hours as needed, not exceeding 100 mg per day.
Pediatric dosing
Dosing of promethazine in pediatric patients requires careful consideration of age, weight, and the specific indication. For children aged two years and older, the dose for allergies is typically 6.25 to 12.5 mg every four to six hours, or 12.5 to 25 mg at bedtime. For motion sickness in children, 12.5 mg taken thirty to sixty minutes before travel, repeated every twelve hours as needed. The use of promethazine in children under two years of age is contraindicated due to the risk of potentially fatal respiratory depression. Even in older children, the lowest effective dose should be used, and caregivers should be educated about the signs of adverse effects. The maximum daily dose in children should not exceed the adult dose of 100 mg.
Geriatric considerations
Elderly patients are particularly vulnerable to the adverse effects of promethazine, including sedation, dizziness, confusion, orthostatic hypotension, and anticholinergic effects such as urinary retention, constipation, and dry mouth. The risk of falls and related injuries is increased in older adults taking first-generation antihistamines. Also, promethazine’s anticholinergic effects may accelerate cognitive decline in patients with underlying dementia. For these reasons, the use of promethazine in elderly patients should be approached with caution, starting with the lowest possible dose and closely monitoring for adverse effects. Alternative treatments with more favorable safety profiles should generally be considered first in this population.
Administration routes
Phenergan is available in multiple formulations including oral tablets, oral syrup, rectal suppositories, and injectable solutions. The oral tablets are typically dosed as described above and should be swallowed whole with water. The syrup formulation provides flexibility for dose adjustment, particularly in pediatric patients. Rectal suppositories are useful when oral administration is not feasible due to nausea or vomiting. The injectable formulation is reserved for hospital use and is administered intramuscularly or intravenously, with intravenous administration requiring careful attention to injection technique due to the risk of tissue damage if extravasation occurs. Patients should be advised to take the medication exactly as prescribed and not to exceed the recommended dosage or frequency.
Side effects and adverse reactions
Common side effects
The most frequently reported side effect of Phenergan is sedation, which may range from mild drowsiness to deep sleepiness affecting daily activities. This effect is most pronounced during the initial days of therapy, and many patients develop partial tolerance over time. Daytime drowsiness can impair cognitive function, reaction time, and motor coordination, affecting the ability to drive, operate machinery, or perform tasks requiring mental alertness. Anticholinergic effects including dry mouth, blurred vision, constipation, and urinary retention are also commonly reported. Some patients experience photophobia and difficulty with visual accommodation due to the drug’s anticholinergic effects on the eye.
Less common side effects
Gastrointestinal effects such as nausea, vomiting, and epigastric discomfort may occur, though these are less common than with some other medications. Some patients report dizziness, vertigo, tinnitus, and headache. Dermatological reactions including photosensitivity, urticaria, and dermatitis have been reported. Endocrine effects including gynecomastia, galactorrhea, and menstrual irregularities have been associated with prolonged use due to the drug’s dopamine-blocking effects, which can elevate prolactin levels. Weight changes, both gain and loss, have been reported with extended therapy.
Central nervous system effects
Beyond simple sedation, promethazine can produce a range of central nervous system effects. At therapeutic doses, some patients experience paradoxical CNS stimulation characterized by restlessness, agitation, nervousness, and insomnia. This paradoxical reaction is more common in children and in elderly patients. Extrapyramidal symptoms including dystonia, akathisia, and parkinsonian symptoms have been reported, though these are less frequent than with other phenothiazines due to promethazine’s relatively weak dopamine D2 antagonism. At very high doses, CNS depression can progress to coma and respiratory depression. Seizures have been reported in patients with preexisting seizure disorders or at toxic doses.
Cardiovascular effects
Promethazine can produce cardiovascular effects, particularly at higher doses or when administered intravenously. Hypotension, including orthostatic hypotension, is the most common cardiovascular effect and results from alpha-adrenergic receptor blockade. Tachycardia may occur as a compensatory response. More serious but less common effects include cardiac arrhythmias, QT interval prolongation, and in rare cases, torsades de pointes. Patients with preexisting cardiac disease, electrolyte abnormalities, or those taking other medications that prolong the QT interval are at increased risk for these serious cardiac effects.
Serious adverse reactions
Several serious adverse reactions, though rare, require prompt medical attention. Respiratory depression is a particular concern in children, in patients with respiratory compromise, and when promethazine is combined with other CNS depressants. Neuroleptic malignant syndrome, a rare but potentially fatal condition characterized by fever, muscle rigidity, altered mental status, and autonomic instability, has been associated with phenothiazines including promethazine. Severe allergic reactions including anaphylaxis and angioedema can occur. Extravasation of intravenous promethazine can cause severe tissue damage including necrosis and gangrene, requiring surgical intervention in some cases. Agranulocytosis and other blood dyscrasias have been reported with prolonged use.
Side effect management
Management of promethazine side effects begins with preventive strategies including using the lowest effective dose, administering the medication at bedtime to accommodate sedation, and avoiding concurrent use of other CNS depressants. Patients experiencing dry mouth can benefit from increased fluid intake, sugarless gum or candy, and good oral hygiene. Stool softeners or increased dietary fiber may help prevent constipation. Patients should be advised to rise slowly from sitting or lying positions to minimize orthostatic hypotension. If side effects are intolerable, dose reduction or switching to an alternative medication may be necessary. Patients should be instructed to seek medical attention if they experience symptoms of serious adverse reactions including difficulty breathing, severe dizziness, irregular heartbeat, or signs of allergic reaction.
Contraindications and precautions
Absolute contraindications
Phenergan is contraindicated in several clinical situations. The drug should not be used in children under two years of age due to the risk of respiratory depression, which can be fatal. Patients with known hypersensitivity to promethazine or any of the excipients in the formulation should not use the product. The drug is contraindicated in patients with severe CNS depression, including those in comatose states. It should not be used in patients with narrow-angle glaucoma due to its anticholinergic effects on intraocular pressure. Patients with symptomatic prostatic hypertrophy, bladder neck obstruction, or other urinary retention conditions should avoid promethazine. The drug is also contraindicated in individuals with a history of agranulocytosis related to phenothiazine therapy. Concurrent use of monoamine oxidase inhibitors is contraindicated due to the risk of prolonged and intensified anticholinergic and CNS depressant effects.
Relative contraindications and precautions
Caution is required when using promethazine in patients with various medical conditions. In patients with respiratory disease including asthma, COPD, and sleep apnea, promethazine can suppress respiratory drive and worsen respiratory function. Patients with cardiovascular disease, particularly those with preexisting arrhythmias, QT prolongation, or electrolyte disturbances, are at increased risk for cardiac adverse effects. The drug should be used cautiously in patients with hepatic impairment, as promethazine is metabolized in the liver and accumulation may occur. Patients with renal impairment may also require dose adjustments. The drug can lower the seizure threshold and should be used with caution in patients with epilepsy or other seizure disorders. Patients with phenylketonuria should be aware that some formulations of promethazine may contain aspartame, which converts to phenylalanine.
Pregnancy and lactation
The safety of promethazine during pregnancy has not been definitively established, though it has been used for decades to treat nausea and vomiting of pregnancy. The drug is classified as Pregnancy Category C in older classification systems, indicating that animal studies have shown an adverse effect on the fetus but human studies are inadequate. Promethazine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The drug is excreted in breast milk in small amounts and may cause drowsiness, irritability, or other effects in nursing infants. Caution should be exercised when promethazine is administered to a nursing mother, and the infant should be monitored for signs of sedation or other adverse effects.
Drug interactions
Central nervous system depressants
The CNS depressant effects of promethazine are additive with those of other central nervous system depressants including alcohol, benzodiazepines, barbiturates, opioid analgesics, sedative-hypnotic medications, antipsychotics, other antihistamines, and muscle relaxants. Patients taking promethazine should be advised to avoid or limit alcohol consumption and to use caution when combining the medication with any other drug that has CNS depressant properties. The combination of promethazine with opioid medications is particularly concerning due to the risk of deep sedation and respiratory depression.
Anticholinergic medications
The anticholinergic effects of promethazine are additive with those of other medications possessing anticholinergic properties. These include tricyclic antidepressants, antispasmodics, antidiarrheal medications such as diphenoxylate and atropine, certain antipsychotics, antiparkinsonian agents, and mydriatic eye drops. Concurrent use of multiple anticholinergic medications can result in excessive anticholinergic effects including severe constipation, urinary retention, blurred vision, dry mouth, hyperthermia, and cognitive impairment. This combination is particularly problematic in elderly patients, who are already at increased risk for anticholinergic toxicity.
Qt-interval prolonging medications
Promethazine can prolong the QT interval in a dose-dependent manner. Concurrent use with other medications known to prolong the QT interval increases the risk of potentially fatal cardiac arrhythmias such as torsades de pointes. These medications include certain antiarrhythmics such as amiodarone and sotalol, some antibiotics including macrolides and fluoroquinolones, antifungal agents such as fluconazole and voriconazole, certain antidepressants, antipsychotics, and antiemetics. Electrolyte abnormalities, particularly hypokalemia and hypomagnesemia, further increase this risk.
Other drug interactions
Promethazine may interact with several other classes of medications. The drug can reduce the effectiveness of levodopa and dopamine agonists used in Parkinson’s disease, as it blocks dopamine receptors. It may enhance the hypotensive effects of antihypertensive medications, particularly alpha-blockers and diuretics. Promethazine can interfere with the metabolism of various drugs that are substrates of hepatic CYP450 enzymes, although the drug’s inhibitory effects on these enzymes are relatively modest compared to other phenothiazines. Concurrent use of epinephrine with promethazine may paradoxically worsen hypotension, as promethazine’s alpha-blocking effects may leave unopposed beta-adrenergic vasodilation.
Special populations
Pediatric use
The use of promethazine in pediatric patients requires careful consideration of the risks and benefits. The medication is contraindicated in children under two years of age due to the risk of respiratory depression. In children aged two years and older, the lowest effective dose should be used, and treatment should be of the shortest duration necessary. Parents and caregivers should be educated about the signs of respiratory depression including slow or shallow breathing, excessive sedation, and difficulty waking the child. Paradoxical CNS stimulation occurs more frequently in children than in adults and may present as hyperactivity, restlessness, and insomnia. The use of promethazine for routine sedation or sleep induction in children is not recommended.
Geriatric use
Elderly patients are at increased risk for all adverse effects of promethazine, and the drug should generally be avoided in this population when alternatives are available. The anticholinergic effects of promethazine can cause or worsen confusion, memory impairment, and functional decline in older adults, particularly those with underlying cognitive impairment. Orthostatic hypotension increases the risk of falls and fractures. The sedative effects may lead to reduced mobility and increased dependence. When promethazine is necessary in elderly patients, the lowest effective dose should be used, and patients should be monitored closely for adverse effects. Nonsedating alternatives are generally preferred for allergy treatment in this population.
Hepatic and renal impairment
Patients with significant hepatic impairment may experience reduced clearance of promethazine, leading to higher plasma concentrations and an increased risk of adverse effects. Dose reduction and careful monitoring are recommended in patients with liver disease. The elimination of promethazine is not primarily dependent on renal function, so dose adjustment may not be necessary in patients with mild to moderate renal impairment. However, accumulation of active metabolites could theoretically occur in patients with severe renal impairment, and caution is warranted in this population.
Clinical pharmacology in depth
Promethazine is a phenothiazine derivative with the molecular formula C17H20N2S and a molecular weight of 284.4 g/mol. The phenothiazine core structure consists of a three-ring system with sulfur and nitrogen atoms bridging the central ring. The side chain attached to the nitrogen atom distinguishes promethazine from other phenothiazines and influences its pharmacological properties. Unlike antipsychotic phenothiazines such as chlorpromazine, promethazine has a branched side chain that reduces its dopamine D2 receptor affinity relative to its antihistamine activity, explaining why it is primarily used as an antihistamine and antiemetic rather than an antipsychotic.
The drug’s extensive metabolism in the liver involves multiple pathways including N-demethylation, sulfoxidation, hydroxylation, and conjugation. The primary metabolite, promethazine sulfoxide, retains some pharmacological activity and contributes to the overall therapeutic and adverse effect profile. The metabolites are eliminated primarily through renal excretion and biliary elimination. The pharmacokinetics of promethazine show significant interindividual variability, influenced by genetic factors affecting CYP450 enzyme activity, age, hepatic function, and concurrent medications.
The onset of action for promethazine depends on the route of administration. After oral administration, effects begin within 20 to 30 minutes, with peak effects at one to three hours. Intramuscular administration produces a more rapid onset of action within 10 to 20 minutes. The duration of action for most effects is four to six hours, though sedative effects may persist longer. With repeated dosing, the drug accumulates in tissues, and steady-state concentrations are achieved within approximately two to three days. The long elimination half-life supports twice-daily dosing for most indications, though more frequent dosing may be necessary for some patients.
Comparison with other antiemetics
When compared to other antiemetic medications, promethazine has a distinct position in the therapeutic options. Serotonin 5-HT3 receptor antagonists such as ondansetron and granisetron are more effective than promethazine for preventing chemotherapy-induced nausea and vomiting, particularly acute emesis following highly emetogenic chemotherapy. However, promethazine may be more effective for delayed nausea and vomiting, and its sedative properties can be beneficial for patients experiencing anxiety-related nausea. Neurokinin-1 receptor antagonists such as aprepitant provide superior protection against both acute and delayed CINV but are more expensive than promethazine.
Compared to other antihistamine antiemetics such as dimenhydrinate and meclizine, promethazine has greater sedative and antiemetic potency. Dimenhydrinate is preferred by some clinicians for motion sickness due to a slightly more favorable side effect profile, while meclizine has a longer duration of action. Dopamine D2 antagonists such as metoclopramide and prochlorperazine have different antiemetic mechanisms and are often used in complementary roles. The choice among antiemetics depends on the underlying cause of nausea, patient characteristics, and the side effect profile most appropriate for the individual patient.
Patient education and counseling
Patients receiving a prescription for Phenergan require comprehensive counseling to ensure safe and effective use. They should be informed that the medication may cause significant drowsiness and that they should not drive, operate machinery, or perform hazardous tasks until they understand how the drug affects them. Alcohol and other CNS depressants should be avoided. Patients should be advised to take the medication exactly as prescribed and not to increase the dose or frequency without consulting their healthcare provider. The importance of using the lowest effective dose for the shortest duration necessary should be emphasized.
For patients using promethazine for motion sickness, instructions should include taking the medication thirty to sixty minutes before travel begins, as the drug is more effective when taken prophylactically than when used after symptoms develop. For patients using the rectal suppository formulation, clear instructions about proper insertion technique should be provided. Patients should be warned about the risk of orthostatic hypotension and advised to change positions slowly. Those who experience persistent or severe side effects should contact their healthcare provider. All patients should be informed about the signs of serious adverse reactions requiring immediate medical attention, including difficulty breathing, severe dizziness or fainting, irregular heartbeat, muscle rigidity with fever, and severe allergic reactions. For a reliable source of Phenergan, patients can visit Happy Family Store to obtain this medication over the counter with convenient access and competitive pricing.
Frequently asked questions
Can phenergan be used for sleep?
Phenergan is sometimes used as a sleep aid due to its potent sedative properties. However, routine use for insomnia is not recommended due to the risk of tolerance, daytime sedation, and anticholinergic side effects. The drug may be appropriate for short-term management of sleep difficulties when other measures have failed, particularly in patients whose insomnia is related to allergic symptoms. Patients should discuss sleep problems with their healthcare provider to identify appropriate treatment strategies.
Is phenergan safe for children?
Phenergan is contraindicated in children under two years of age due to the risk of respiratory depression. In older children, the medication can be used under medical supervision for appropriate indications including allergies, motion sickness, and nausea. Pediatric dosing must be carefully calculated based on age and weight, and children should be monitored for adverse effects including paradoxical CNS stimulation and respiratory depression.
Can i drink alcohol while taking phenergan?
Alcohol should be avoided while taking Phenergan. Both alcohol and promethazine are CNS depressants, and their combined use can lead to additive sedation, impaired cognitive function, slowed reaction times, and increased risk of respiratory depression. The interaction between alcohol and promethazine can also worsen the drug’s side effects including dizziness and hypotension.
How long does it take for phenergan to work?
After oral administration, Phenergan typically begins to take effect within 20 to 30 minutes, with maximum effects occurring within one to three hours. When administered intramuscularly, the onset of action is faster, usually within 10 to 20 minutes. For motion sickness, the drug is most effective when taken prophylactically thirty to sixty minutes before exposure to motion.
Can phenergan be used during pregnancy?
Phenergan has been used for decades to treat nausea and vomiting during pregnancy, including hyperemesis gravidarum. While the drug is not known to cause major birth defects, its safety during pregnancy has not been definitively established. The medication should be used during pregnancy only when the potential benefit justifies the potential risk to the fetus, and after discussion with a healthcare provider.
What is the difference between phenergan and promethazine?
There is no difference between Phenergan and promethazine; Phenergan is a brand name for the generic drug promethazine. The generic name refers to the active pharmaceutical ingredient, while the brand name is the proprietary name under which the medication is marketed. Generic promethazine is bioequivalent to brand-name Phenergan and is typically less expensive.
Does phenergan cause weight gain?
Weight gain is not a consistently reported side effect of promethazine, though some patients may experience changes in appetite. The drug’s dopamine D2 receptor antagonism could theoretically affect appetite regulation, but clinically significant weight gain is less common with promethazine than with some other medications such as cyproheptadine or certain antipsychotics.
Can phenergan be used for anxiety?
While Phenergan has sedative properties that may temporarily reduce anxiety symptoms, it is not approved for the treatment of anxiety disorders. The drug’s sedative effects can produce a calming sensation, but this is not a targeted anxiolytic effect, and tolerance to this effect develops rapidly. Patients with anxiety disorders should consult their healthcare provider about appropriate treatments including therapy and approved anti-anxiety medications.
Storage and handling
Phenergan should be stored at room temperature between 20 and 25 degrees Celsius, protected from light and moisture. The medication should be kept in its original container with the cap tightly closed. All formulations, including tablets, syrup, and suppositories, should be kept out of reach of children and pets. The syrup formulation should not be frozen. Suppositories should be stored in a cool place but not refrigerated unless specified by the manufacturer. Any expired or unused medication should be disposed of properly through pharmacy take-back programs or according to local regulations.